nyuuzyou/wikis huggingface dataset:
Vonoprazan (Takecab)

Acid pump antagonist
==History of changes in PMDA indication==
*2014-12-26: Initial approval for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer.
==Also known as==
*Generic name: vonoprazan fumarate
*Brand name: Takecab
Category:Drugs
Category:Oral medications
Category:Acid pump antagonists
Category:PMDA approved in 2014
Category:Stub
Vorapaxar (Zontivity)

==General information==
Class/mechanism: inhibits thrombin-related platelet aggregation.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==History of changes in FDA indication==
*2014-05: Initial approval for the reduction of thrombotic cardiovascular events in patients with prior MI or with PAD.
==Also known as==
*Brand name: Zontivity
Category:Drugs
Category:Oral medications
Category:PAR1 inhibitors
Category:FDA approved in 2014
Vorasidenib (Voranigo)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically inhibits mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH mutations. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB).
==Diseases for which it is established==
*Low-grade glioma
==History of changes in FDA indication==
*2024-08-06: Approved for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. (Based on INDIGO)
==Also known as==
*Code name: AG-881
*Brand name: Voranigo
Category:Drugs
Category:Mutation-specific medications
Category:Oral medications
Category:IDH1 inhibitors
Category:IDH2 inhibitors
Category:Low-grade glioma medications
Category:FDA approved in 2024
Voriconazole (Vfend)

Azole antifungal, no known antineoplastic properties.
==Also known as==
*Brand names: Ortrex, Orvor, Reconaz, Verz, Vfend, Vonaz, Voraze, Voricort, Vorier, Vorirx, Voritek, Voritrol, Voriva, Vorizol, Vorwell, Vorzole, Vorzu
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Antifungals
Category:FDA approved in 2002
Category:WHO Essential Anti-infective Medicines
Vorolanib (CM-082)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with antiangiogenic and antineoplastic activities. Vorolanib inhibits all isoforms of VEGFR and PDGFR, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and PDGFRs are receptor tyrosine kinases that may be upregulated in various tumor cell types. VEGFR/PDGFR dual kinase inhibitor X-82 has been shown to reduce tissue toxicity by 95 percent compared with first-generation kinase inhibitors.
==Also known as==
*Code names: CM-082, X-82
Category:Drugs
Category:Oral medications
Category:VEGFR inhibitors
Category:PDGFR inhibitors
Category:Renal cell carcinoma medications (investigational)
Category:Investigational drugs
Voxelotor (Oxbryta)

Note: This drug was voluntarily withdrawn from global markets by the manufacturer on 2024-09-25.
==General information==
Class/mechanism: hemoglobin S (HbS) polymerization inhibitor. Voxelotor inhibits hemoglobin S polymerization and red blood cell sickling by increasing the affinity of hemoglobin for oxygen.Voxelotor (Oxbryta) package insert Voxelotor (Oxbryta) package insert (locally hosted backup)Oxbryta manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it was used==
*Sickle cell anemia
==Patient drug information==
*Voxelotor (Oxbryta) package insert
*Voxelotor (Oxbryta) patient drug information (UpToDate)Voxelotor (Oxbryta) patient drug information (UpToDate)
==History of changes in FDA indication==
*2019-11-25: Granted FDA accelerated approval "for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older." in adults and pediatric patients 12 years of age and older.
*2021-12-17: Granted FDA accelerated approval "to treat sickle cell disease in pediatric patients aged four up to 11 years" in addition to previous accelerated approval for Oxbryta for patients aged 12 years and older with sickle cell disease. 
==History of changes in EMA indication==
*2022-02-14: Initial EMA authorization
==Also known as==
*Code names: GBT-440, GTx-011
*Brand name: Oxbryta
==References==
Category:Drugs
Category:Oral medications
Category:Hemoglobin S polymerization inhibitors
Category:Sickle cell anemia medications (historical)
Category:EMA approved in 2022
Category:FDA approved in 2019
Category:Discontinued drugs
Category:Pfizer product
Vulvar cancer

Back to Top
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ESGO==
*2023: Oonk et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023 EuroPMC
==NCCN==
*NCCN Guidelines - Vulvar Cancer
**2024: Abu-Rustum et al. Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology EuroPMC
**2017: Koh et al. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. EuroPMC
=Neoadjuvant therapy=
==Cisplatin & RT==
Cisplatin & RT: Cisplatin & Radiation Therapy
===Regimen===
Study 	Dates of enrollment 	Evidence
Moore et al. 2011	2005-01-19 to 2009-09-21	Phase 2
====Chemotherapy====
*Cisplatin (Platinol) 40 mg/m2 IV once per day on days 1, 8, 15, 22, 29, 36, 43
====Radiotherapy====
*Concurrent radiation therapy 180 cGy per day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, 36 to 40, 43, 44 (32 fractions, for a dose of 5760 cGy)
6.5-week course
====Subsequent treatment====
*Surgical resection of residual disease (or biopsy to confirm CR)
===References===
# Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, Homesley HD, Walker JL. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Mar;124(3):529-33. Epub 2011 Nov 9. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
=Locally advanced or metastatic disease=
Due to its relative rarity, there are very few prospective trials in advanced and metastatic vulvar cancer. In clinical practice, many adopt regimens from the cervical cancer literature; see the cervical cancer page for those regimens.
==Paclitaxel monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Witteveen et al. 2009 (EORTC 55985)	2001-02 to 2004-12 	Phase 2
====Chemotherapy====
*Paclitaxel (Taxol) 175 mg/m2 IV once on day 1
21-day cycle for up to 10 cycles
===References===
# EORTC 55985: Witteveen PO, van der Velden J, Vergote I, Guerra C, Scarabeli C, Coens C, Demonty G, Reed N; EORTC. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). Ann Oncol. 2009 Sep;20(9):1511-6. Epub 2009 Jun 1. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
Category:Vulvar cancer regimens
Category:Disease-specific pages
Category:Gynecologic cancers
WHIM syndrome

Back to Top
WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
Last updated on 2024-09-06:2 regimens on this page
2 variants on this page
=All lines of therapy=
==Mavorixafor monotherapy==
===Regimen===
Study 	Dates of enrollment [xx]	Evidence 	Comparator	Comparative Efficacy
Badolato et al. 2024 (4WHIM)	2019-10-24 to 2021-09-09	Phase 3 (E-esc)	Placebo 	Longer time (hours) above ANC threshold 500/uL
====Growth factor therapy====
*Mavorixafor (Xolremdi) by the following age- and weight-based criteria:
**Adults: 400 mg PO once per day
**Adolescents more than 50 kg: 400 mg PO once per day
**Adolescents up to 50 kg: 200 mg PO once per day
Continued indefinitely
===References===
#4WHIM: Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, Dale D, Deyà-Martínez À, Dickerson KE, Ezra N, Hasle H, Kang HJ, Kiani-Alikhan S, Kuijpers TW, Kulagin A, Langguth D, Levin C, Neth O, Olbrich P, Peake J, Rodina Y, Rutten CE, Shcherbina A, Tarrant TK, Vossen MG, Wysocki CA, Belschner A, Bridger GJ, Chen K, Dubuc S, Hu Y, Jiang H, Li S, MacLeod R, Stewart M, Taveras AG, Yan T, Donadieu J. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024 Jul 4;144(1):35-45. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03995108
==Plerixafor monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
McDermott et al. 2019	Not reported 	Pilot, fewer than 20 pts
====Growth factor therapy====
*Plerixafor (Mozobil) 0.01 to 0.02 mg/kg SC twice per day
Various durations
===References===
# Case series: McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
Category:WHIM syndrome regimens
Category:Disease-specific pages
Category:Cytopenias
Warfarin (Coumadin)

==General information==
Class/mechanism: Vitamin K antagonist, inhibits the production of several vitamin K-dependent clotting factors, such as factor II (prothrombin), factor VII (proconvertin), factor IX (plasma thromboplastin component), factor X (Stuart factor), protein C, and protein S. Warfarin interferes with regeneration of vitamin K1 epoxide by inhibiting the C1 subunit of vitamin K epoxide reductase (VKORC1). Some nucleotide polymorphisms in VKOR and CYP2C9 variants have been associated with different warfarin dose requirements.Warfarin (Coumadin) package insert Warfarin (Coumadin) package insert (locally hosted backup)Coumadin manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
*Warfarin (Coumadin) package insert
*Warfarin (Coumadin) patient drug information (UpToDate)Warfarin (Coumadin) patient drug information (UpToDate)
==Diseases for which it is used==
*Antiphospholipid antibody syndrome
*Venous thromboembolism
==Also known as==
*Generic name: warfarina sodica
*Brand names:
Synonyms 	Synonyms 	Synonyms 	Synonyms	Synonyms 	Synonyms	Synonyms 	Synonyms
Aldocumar 	Anasmol 	Anticoag 	Arefarin	Athrombin-K	Befarin 	Caumadin 	Cicoxil
Circuvit 	Coumadin 	Coumadine 	Couparin	Dagonal 	Farin 	Ferevan 	Fericard
Haemofarin	Jantoven 	Kovar 	Lawarin 	Maforan 	Marfarin	Marivanil	Marivarin
Orfarin 	Panwarfin	Panwarfine	Romesa 	Samofaron 	Simarc 	Tedicumar	Varfarins
Varfine 	Waran 	Warf 	Warfa 	Warfant 	Warfar 	Warfarex 	Warfil
Warfilone 	Warfin 	Warin 	Warlin 	Warnerin 	Werifrin	 	
==References==
Category:Drugs
Category:Oral medications
Category:Anticoagulants
Category:Vitamin K antagonists
Category:Antiphospholipid antibody syndrome medications
Category:Venous thromboembolism medications
Category:FDA approved in 1954
Yale-New Haven Hospital Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The goal of the Yale Medical Oncology-Hematology Fellowship Program is to train the next generation of academic hematologists and oncologists devoted to laboratory-based or patient-oriented investigation. Thus, the program is designed and structured to provide not only comprehensive clinical training but also a rigorous research experience to prepare fellows for careers as clinician investigators or clinician scientists in academic medicine."
==Basic information==
Name: Yale Medical Oncology-Hematology Fellowship Program 
Fellowship program website: https://medicine.yale.edu/intmed/medonc/fellowship/program.aspx
ACGME ID: 1550814165
===Leadership===
*Program Director: Jill Lacy, MD
*Associate Program Director: Nikolai Alexandrovich Podoltsev, MD, PhD
*Associate Program Director: Michael E. Hurwitz, PhD, MD
===Fellowship Coordinator===
Lucilina Gilkes
Phone: 203-785-5196
Email: Lucilina.gilkes@yale.edu
==Application process and requirements==
https://medicine.yale.edu/intmed/medonc/fellowship/application.aspx
===Process===
*Applications accepted starting in: July
*Application deadline:
*Applications submitted through ERAS
*Interviews from mid-September to mid-October.
===Requirements===
*Common Application Form (CAF)
*Statement of Personal Goals
*At least three letters of recommendation; one must be from Residency Program Director or Internal Medicine Department Chair
*Foreign medical school graduates: ECFMG certification
*Color Photo
*USMLE transcripts
*Medical School transcripts
*Accept J1 Visa
==Statistics==
*Number of fellowship positions available per year: 8
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
https://medicine.yale.edu/intmed/medonc/fellowship/program.aspx
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Yale-New Haven Hospital
*VA Connecticut Healthcare System, West Haven, CT
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Zanidatamab (Zihera)

==Mechanism of action==
From the NCI Drug Dictionary: A humanized, immunoglobulin G1 (IgG1) bispecific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, with potential immunomodulating and antineoplastic activities. Upon administration, zanidatamab targets and binds to the two distinct HER2 domains on the tumor cell surface. This results in dual HER2 signal blockade, HER2 clustering, receptor internalization and downregulation. This inhibits HER2 activation, HER2-mediated signaling and HER2-mediated tumor cell growth. The specific binding of zanidatamab to tumor cells and HER2 aggregation also activates various immune-mediated responses, and induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) against tumor cells that overexpress HER2.
==Diseases for which it is used==
*Biliary tract cancer (BTC)
==History of changes in FDA indication==
*2024-11-20: Granted accelerated approval for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. (Based on HERIZON-BTC-01)
==Also known as==
*Generic name: zanidatamab-hrii
*Brand name: Zihera
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-HER2 bispecific antibodies
Category:Biliary tract cancer medications
Category:FDA approved in 2024
Zenocutuzumab (Bizengri)

==Mechanism of action==
From the NCI Drug Dictionary: A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab-zbco may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab-zbco is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.
==Diseases for which it is used==
*Non-small cell lung cancer
*Pancreatic cancer
==History of changes in FDA indication==
*2024-12-04: Granted accelerated approved for adults with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. (Based on eNRGy)
*2024-12-04: Granted accelerated approved for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy. (Based on eNRGy)
==Also known as==
*Code name: MCLA-128
*Generic name: zenocutuzumab-zbco
*Brand name: Bizengri
Category:Drugs
Category:Intravenous medications
Category:Mutation-specific medications
Category:Anti-HER2-HER3 bispecific antibodies
Category:Non-small cell lung cancer medications
Category:Pancreatic cancer medications
Category:FDA approved in 2024
Zidovudine (Retrovir)

==Mechanism of action==
From the NCI Drug Dictionary: A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines.
==Diseases for which it is used==
*Adult T-cell leukemia-lymphoma
==Also known as==
*Generic names: azidothymidine, AZT, ZDV
*Brand names: Aztec, Retrovir
Category:Drugs
Category:Oral medications
Category:Viral DNA synthesis inhibitors
Category:Adult T-cell leukemia-lymphoma medications
Category:FDA approved in 1987
Zimberelimab (Yu Duo)

==Mechanism of action==
PD-1 inhibitor
==Diseases for which it is used==
*Classical Hodgkin lymphoma
==History of changes in NMPA indication==
*2021-08-30: Approved for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).
==Also known as==
*Code names: AB-122, GLS-010, WBP-3055
*Generic name: sepalizumab
*Brand name: Yu Duo
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-1 antibodies
Category:Classical Hodgkin lymphoma medications
Category:NMPA approved in 2021
Zinpentraxin alfa (PRM-151)

==General information==
Class/mechanism per NCI Drug Dictionary: A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant human serum amyloid P/pentraxin 2 (PRM-151) may inhibit myofibroblast generation by preventing the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages. PTX2 is a circulating plasma protein that belongs to the class of pattern recognition receptors (PRR) of the innate immune system.
Route: IV
Extravasation: n/a
==Also known as==
*Code name: PRM-151
Category:Drugs
Category:Intravenous medications
Category:Recombinant medications
Category:Myelofibrosis medications (investigational)
Category:Investigational drugs
Category:Stub
Ziv-aflibercept (Zaltrap)

==General information==
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.Ziv-aflibercept (Zaltrap) package insertZiv-aflibercept (Zaltrap) package insert (locally hosted backup)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Colorectal cancer
==Patient drug information==
*Ziv-aflibercept (Zaltrap) package insert.
*Ziv-aflibercept (Zaltrap) patient drug information (Chemocare)Ziv-aflibercept (Zaltrap) patient drug information (Chemocare)
*Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2012-08-31: Initial FDA approval in combination with 5-fluorouracil, leucovorin, irinotecan - ( FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. (Based on VELOUR)
==History of changes in EMA indication==
*2013-02-01: Initial marketing authorization as Zaltrap.
==History of changes in Health Canada indication==
*2014-02-12: Initial notice of compliance
==History of changes in PMDA indication==
*2017-03-30: Initial approval for the treatment of unresectable advanced or recurrent colorectal cancer.
==Also known as==
*Generic names: aflibercept, aflibercept beta, VEGF trap, ziv-aflibercept
*Brand names: Zaltrap
==References==
Category:Drugs
Category:Intravenous medications
Category:VEGFR inhibitors
Category:Soluble decoy receptors
Category:Colorectal cancer medications
Category:EMA approved in 2013
Category:FDA approved in 2012
Category:Health Canada approved in 2014
Category:PMDA approved in 2017